17.06.2016 • NewsDede WillamsGlaxoSmithKline (GSK)GSK

GSK Vaccines Head to Step Down

GlaxoSmithKline’s head of vaccines, Moncef Slaoui, has announced he will...
GlaxoSmithKline’s head of vaccines, Moncef Slaoui, has announced he will leave the company in June 2017

GlaxoSmithKline’s head of vaccines, Moncef Slaoui, has announced he will leave the company in June 2017 after nearly three decades at the company. Since joining GSK in 1998, Slaoui has served in a number of positions, including heading R&D operations for eight years.

As chairman of vaccines, he spearheaded the company’s integration of the businesses acquired from Novartis in the $20 billion asset swap agreed in 2014. Slaoui will leave the company in the same year as CEO Andrew Witty, who earlier this year said he would step down in 2017.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.